Vax2Muc consortium reflects on mucosal vaccine research progress in Prague
On 5 – 6 October 2025, the Vax2Muc consortium gathered in Prague for an annual meeting hosted by InStar Technologies, the Czech project partner. Two meeting days were filled with informative presentations about recent project progress and lively discussion concerning the next steps in the consortium’s work towards developing vaccines against pathogens in the gastrointestinal tract, such as H. pylori.
The updates from the different project activities, known as Work Packages, highlighted the varied ongoing research involved in vaccine development, some of which has already been presented at conferences recently.
One of the highlights of the latest project period was the excellent collaboration among our international partners. Earlier this year, Cora Mibus and PD Dr Raquel Mejías-Luque from the Technical University of Munich visited their colleagues at the Institute of Agrifood Research and Technology (IRTA) in Barcelona. Specifically, they focused on laboratory work, isolating H. pylori from the pigs’ stomach samples.
Continuous support and knowledge exchange among partners is essential to scientific projects like Vax2Muc, significantly benefiting everyone involved.
Overall, the project is progressing in line with the plans. As the ongoing research by partners throughout Europe produces more results, the focus is shifting towards dissemination efforts and stakeholder engagement. With these upcoming activities, the partners will present results at conferences and in publications, contributing to the efforts in the field of mucosal vaccines and the fight against stomach cancer.
To follow the consortium’s work, be sure to check out the publication and news pages.
